EU antitrust regulators to investigate Mars' $36 bln Kellanova deal

EU antitrust regulators have initiated a full-scale investigation into Mars' proposed $36 billion acquisition of Kellanova, citing concerns that the merger could significantly harm competition and lead to higher consumer prices due to Mars' increased negotiating power with retailers in the European Economic Area. The European Commission, which received formal notification on May 16, 2025, has until October 31, 2025, to render a decision, signaling substantial regulatory scrutiny for the transaction.

Analysis

The European Commission has initiated a full-scale, in-depth investigation into Mars' proposed $36 billion acquisition of Kellanova (K.N), signaling a significant regulatory obstacle for the deal. The core concern cited by antitrust authorities is that the merger would substantially increase Mars' negotiating power with retailers across the European Economic Area, potentially leading to higher wholesale prices that would ultimately be passed on to consumers. This development confirms earlier reports of anticipated intensive scrutiny and introduces a prolonged period of uncertainty, with a final decision not expected until October 31, 2025. While the opening of an in-depth inquiry is a standard procedural step and does not predetermine the outcome, it materially increases the risk profile of the transaction, raising the probability that the deal could be blocked or require substantial divestitures to secure approval.

Key Decisions for Investors

• Investors in Kellanova (K.N) should recognize the heightened risk to the deal's completion, as a full-scale EU probe introduces significant uncertainty and a potential downside catalyst for the stock if the acquisition fails.
• Merger arbitrage specialists should anticipate a widening of the spread between Kellanova's share price and the deal price, reflecting the increased probability of a negative regulatory outcome or extended timeline.
• Monitor for any statements from Mars or the Commission regarding potential remedies or concessions, as these will be the key indicators of the deal's viability ahead of the October 31, 2025 deadline.